Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Post‐marketing analysis for biosimilar CT‐P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan

Published:2021-01-31 Issue:8 Volume:36 Page:2091-2100
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Sagami Shintaro¹²^ORCID,Nishikawa Kiyohiro³⁴^ORCID,Yamada Fumika³^ORCID,Suzuki Yasuo⁵,Watanabe Mamoru⁶^ORCID,Hibi Toshifumi¹^ORCID

Affiliation:

1. Center for Advanced IBD Research and Treatment Kitasato University Kitasato Institute Hospital Tokyo Japan

2. Department of Gastroenterology and Hepatology Kitasato University Kitasato Institute Hospital Tokyo Japan

3. Quality and Pharmacovigilance Division Pharmaceuticals Group, Nippon Kayaku Co., Ltd. Tokyo Japan

4. Asajes Ventures Tokyo Japan

5. IBD Center Toho University Sakura Medical Center Chiba Japan

6. Department of Gastroenterology and Hepatology Tokyo Medical and Dental University Tokyo Japan

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.15399

Reference39 articles.

1. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

2. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

3. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

4. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

5. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Utilization of Generic Drugs and Biosimilars for Ulcerative Colitis Treatment: Insights from a Nationwide Database Study in Japan;Inflammatory Intestinal Diseases;2024

2. Use of external control arms in immune-mediated inflammatory diseases: a systematic review;BMJ Open;2023-12

3. Long-term effectiveness and safety of infliximab-biosimilar: A multicenter Phoenix retrospective cohort study;PLOS ONE;2023-09-12

4. Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies;Drug Safety;2023-09-12

5. Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study;Gastroenterology Research and Practice;2023-03-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3